The award of a $1.3 million contract from NIH to Aligos Therapeutics for the development of a Covid-19 treatment compound is likely to have a positive impact on the company's stock price in the short term. This contract not only provides financial resources but also enhances the company's credibility and visibility in the biotech industry, potentially leading to increased investor confidence. The relevance of this news to ALGS is high, given that it directly involves the company's research and development efforts. The importance is also significant, as successful development could lead to future revenue streams and partnerships. The confidence level in this analysis is based on the direct financial benefit and the potential for positive market perception.